



# TERRASCEND

2024 Third Quarter Financial Results

November 6, 2024

[Terrascend.com](https://www.terrascend.com)

TSX: TSND | OTCQX: TSNDF

# Executive Leadership Speakers



**Jason Wild**

Executive Chairman



**Ziad Ghanem**

President &  
Chief Executive Officer



**Keith Stauffer**

Chief Financial Officer

# Disclaimer

## Forward-Looking Information

This presentation contains “forward-looking information” within the meaning of applicable securities laws, including the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information contained in this presentation may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits. Examples of forward-looking information contained in this presentation include the Company’s expectations regarding liquidity and the impact of its refinancing; the Company’s expectations regarding its share repurchase program; the Company’s growth strategy; the Company’s announced agreement to acquire Ratio Cannabis and its ability to consummate the proposed acquisition; the Company’s ability to execute on such its M&A strategy, including the outcomes thereof; the Company’s outlook, including the Company’s expected financial results for the fourth quarter of 2024; expectations regarding regulatory reforms, and the benefits thereof; and the likelihood of approval of adult-use cannabis in Pennsylvania and related opportunities.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, our recent growth, which may not be indicative of our future growth; current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) and in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2024, and any subsequently filed quarterly reports on Form 10-Q.

The statements included in this presentation are made as of the date of this presentation. TerrAscend disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

# Disclaimer

## Definition and Reconciliation of Non-GAAP Measures

In addition to reporting the financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company’s ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry. We calculate EBITDA from continuing operations and Adjusted EBITDA from continuing operations and Adjusted EBITDA Margin from continuing operations as net loss adjusted for certain material non-cash items such as inventory write downs outside of the normal course of operations, fees related to the modification of debt, impairment charges taken on goodwill, intangible assets and property and equipment, the gain or loss recognized on the revaluation of our contingent consideration liabilities, gains resulting from the extinguishment of debt, loan modification fees related to the modification of debt, the gain recognized on the extinguishment of debt, the gain or loss on fair value of warrants and purchase option derivative assets, relief of fair value upon acquisition and certain other adjustments management believes are not reflective of the ongoing operations and performance. Furthermore, the Company defines Free Cash Flow as net cash provided by operating activities from continuing operations, adjusted for certain cash items such as capital expenditures for property and equipment. Furthermore, the Company defines General & Administrative expenses excluding stock-based compensation, bad debt and insurance recovery. The Company believes this definition is a useful measure to assess the performance of the Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of the Company’s underlying business performance and other one-time or non-recurring expenses. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are contained in the Appendix to this presentation. The Company has not provided a reconciliation of its forward-looking Adjusted EBITDA Margin with the most directly comparable GAAP measure in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. The Company is unable to calculate the most directly comparable GAAP measure, without unreasonable efforts due to the variability and low visibility with respect to certain costs such as stock-based compensation, certain fair value measurements, tax items, and others that may arise during the period that are not ascertainable.

## Third Party Information

Certain information contained in this presentation and statements made orally during the related earnings webcast relate to or are based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, the Company has not independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of the Company’s internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

# Overview

Jason Wild, Executive Chairman

# Q3 2024 Financial Highlights

**Our core business remained solid during Q3 as we maintained market leadership positions in our key markets, including a #1 market share position in New Jersey**



**\$74.2 M**  
Net Revenue



**9<sup>th</sup> Consecutive**  
Quarter of Positive  
Cash Flow from  
Continuing Operations



**\$1.8 M**  
Cash Flow from  
Continuing Operations



**48.8%**  
Gross Profit Margin



**5<sup>th</sup> Consecutive**  
Quarter of Positive Free  
Cash Flow\*



**\$1.5 M**  
Free Cash Flow\*



**\$13.7 M**  
Adjusted EBITDA from  
Continuing Operations\*

\* Adjusted EBITDA from continuing operations, Adjusted EBITDA Margin from continuing operations, and Free Cash Flow are non-GAAP measures defined in the section titled “Definition and Reconciliation of Non-GAAP Measures” and reconciled to the most directly comparable GAAP measure in the Appendix at the end of this presentation.

# Active Pursuit of Greenfield Expansion Opportunities

Uniquely positioned to enter new markets through attractive M&A, such as Ohio




Population

**12** Million


**Adult-use commenced  
on August 6th**

- Targeted approach puts us in a differentiated position to invest in the best geographies and assets at attractive valuations with minimal competitive tension.
- Population of 12 million, compared to 9 million in NJ and 6 million in MD.
- Began adult-use in August 2024.
- Plan to leverage existing SG&A infrastructure in the Midwest, making MI and OH more profitable combined rather than as standalone entities.
- Continue to have many other ongoing M&A conversations.



# Signed Definitive Agreement to Enter Ohio through the Acquisition of a High-Performing Dispensary

- Ohio, early days of implementing adult-use.
- Upon closing, TerrAscend's first entry into 6<sup>th</sup> state.
- Intention is to assemble a leading retail footprint in Ohio by acquiring high-quality stores, just as was done successfully in Maryland.
- In each geography, goal is to be a market leader; Ohio and any other new states are no exception.





# Strengthening Balance Sheet is a Priority

- Closed on a \$140 million senior secured loan.
- Matures in August 2028.
- Non-dilutive financing bears a coupon of 12.75%.
- No warrants or prepayment penalties.
- No other material debt maturing until late 2027.
- Financing provides flexibility to pursue attractive M&A transactions that are consistent with our geographic expansion plans.

# Continued Progress With Federal Cannabis Reform

- Encouraged by the upcoming DEA hearing concerning the proposed re-scheduling of cannabis.
- Re-scheduling would result in elimination of punitive tax treatment, provide cannabis companies greater access to capital at reduced costs and unlock restrictions on medical research.
- US Court of Appeals in the First Circuit has scheduled oral arguments in the David Boies lawsuit against US Attorney General Garland, which seeks equal treatment for legal, state regulated cannabis businesses.



# First-Ever Stock Buyback Program for Up to \$10 Million

- In August 2024, commenced first-ever stock buyback program for up to \$10 million, demonstrating confidence in the Company's future and commitment to enhancing shareholder value.
- Since August, purchases were made in open market and will continue to do so opportunistically within the prescribed daily volume restrictions and outside of blackout periods.


# Summary

- Organic growth levers in key states, NJ, MD and PA.
- Ample greenfield expansion opportunities.
- Financial flexibility.
- No material debt maturing for the next several years.

# State-by-State Overview

Ziad Ghanem, President & Chief Executive Officer

# Business Remained Solid Across our Core Markets



# New Jersey

## 3Q '24 Highlights

- Largest and most profitable market.
- According to BDSA, TerrAscend held the #1 market share position through September 2024.
- Brands hold the top 3 positions in flower, vapes, edibles and concentrates.
- In Q3, retail returned to sequential growth for second quarter in a row.
- Wholesale revenue down QoQ and YOY due to heightened market competition.
- Expanding Boonton facility and expect to be operational in early 2025.
- Future growth opportunities for up to 7 additional diversely owned dispensaries.



# Maryland

## 3Q '24 Highlights

- Wholesale revenue increased 26% sequentially due to expanded capacity, now on a \$20 million dollar run rate.
- Added capacity also enabled further gross margin improvement - gross margins have doubled to nearly 50% since the end of 2023.
- Retail revenue remained stable during the quarter.
- Investing in 4 additional grow rooms at the Hagerstown facility, plan to have operational by Q1 of 2025 with first harvests expected in Q2.
- Outlook for additional growth as our additional cultivation capacity comes online next year.





# Pennsylvania

## 3Q '24 Highlights

- Wholesale revenue grew 59% year-over-year, once again driven by value-oriented Legend brand and expansion into edibles with Valhalla.
- Retail declined 11% year-over-year, productivity per store remains healthy and around the state average.
- Optimistic Pennsylvania will turn adult-use in 2025.
- With a population of 12 million, Pennsylvania is already a more than \$1.2 billion medical state and expected to become a \$2 billion plus market under adult-use by 2028.
- As adult-use approaches in 2025, planning to turn on additional cultivation capacity; no additional need for investment.



# Michigan

## 3Q '24 Highlights

- Priorities constant on improving operational efficiency and driving gross margin to establish a solid foundation from which to expand.
- Gross margin remains near 40% year to date.
- Currently operating 20 dispensaries.
- Expect to scale operational footprint in the Midwest by entering new neighboring states to Michigan, such as Ohio to leverage operating expenses more efficiently.
- Michigan remains an important market as the nation's second-largest cannabis market.




# Financial Overview

Keith Stauffer, Chief Financial Officer

# Third Quarter 2024 Net Revenue

**QoQ declines in wholesale revenue in New Jersey and retail revenue in Michigan partially offset by wholesale growth of 26% in Maryland**

**Net Revenue**  
(in millions, US\$)




## Third Quarter 2024 Highlights

- Revenue: \$74.2 million versus \$77.5 million in Q2 2024
- Lower wholesale revenue in New Jersey and retail revenue in Michigan
- Partially offset by wholesale growth of 26% in Maryland

# Gross Profit Margin

Positive trend throughout 2024 driven by improvements in Maryland

## Gross Profit Margin




## Third Quarter 2024 Highlights

- Gross Profit Margin: 48.8% versus 48.6% in Q2 2024 and 48.0% in Q1 2024
- Positive trend throughout the year was driven by improvements in Maryland
- Margins have remained relatively stable in Pennsylvania, New Jersey, and Michigan

# General & Administrative Expenses

Flat QoQ excluding one-time factors\*

## General & Administrative Expenses (in millions, US\$)



## Third Quarter 2024 Highlights

- General & Administrative expenses for Q3 2024, \$31.6 million, compared to \$24.1 million in Q2 2024
- Excluding stock-based compensation expense (SBC) and two one-time factors, G&A expenses were flat quarter-over-quarter
- One-time items include reversals of a bad debt and insurance recovery totaling \$5.0 million

\* General & Administrative expenses excluding stock-based compensation, bad debt and insurance recovery is a non-GAAP measures defined in the section titled “Definition and Reconciliation of Non-GAAP Measures” and reconciled to the most directly comparable GAAP measure in the Appendix at the end of this presentation.

# Net Loss and Adjusted EBITDA\*

## GAAP Net Loss from continuing operations (in millions, US\$)



### GAAP Net Loss:

- \$21.4 million net loss, compared to \$6.2 million net loss in Q2 2023
- Sequential increase in net loss driven by a \$1.9 million reduction in Adj. EBITDA in Q3 as well as several one-time non-cash accounting items in Q2 totaling \$13 million

## Adj EBITDA\* (in millions, US\$)



### Adjusted EBITDA:

- \$13.7 million, or 18.5% of revenue, compared to \$15.6 million, or 20.2% of revenue in Q2 2024
- Sequential decline driven by lower revenue

# Balance Sheet, Cash Flow & Stock Repurchase Program

- Cash, and cash equivalents, including restricted cash:
  - \$27.2 million (9/30/24), compared \$30.5 million (6/30/24)
- Q3 2024 net cash provided by continuing operations:
  - \$1.8 million, representing 9<sup>th</sup> consecutive quarter of positive cash flow from continuing operations
- Q3 2024 Capex was minimal
- Free Cash Flow\*:
  - \$1.5 million, representing 5<sup>th</sup> consecutive quarter of positive free cash flow
- Other Payments:
  - Paid down \$1 million in debt, excluding debt retired through recent refinancing
  - \$2.9 million of distributions to NJ minority partners
- \$140 million senior secured term loan:
  - Coupon rate of 12.75% and a four-year term with no prepayment penalties and no warrants
  - Net proceeds used to pay off existing higher interest debt maturing later this year
- Stock repurchase program:
  - Up to \$10 million of common shares
  - In Q3, repurchased 107,000 shares for \$133,000
  - \$9.87 million remaining



# ERP System

- Multi-year implementation
- Solid IT and financial foundation to enable continued growth, both organically and through M&A
- Improved productivity, lower costs, and more effective decision making

---

## Fourth Quarter 2024 Expectations

- Expect flat to down mid-single digit in revenue sequentially, with stable gross margins, lower G&A expenses, and relatively flat adjusted EBITDA quarter-over-quarter

Thank You

# Appendix – Reconciliation of Non-GAAP Measures

The table below reconciles net loss to EBITDA from continuing operations and Adjusted EBITDA from continuing operations for the quarters ended September 30, 2024 and June 30, 2024.

	For the Three Months Ended	
	September 30, 2024	June 30, 2024
Revenue, net	\$ 74,168	\$ 77,523
Net loss	(21,419)	(6,237)
Net loss margin %	-28.9%	-8.0%
Loss from discontinued operations	—	—
Loss from continuing operations	(21,419)	(6,237)
<i>Add (deduct) the impact of:</i>		
Provision for income taxes	14,373	10,729
Finance expenses	8,610	9,132
Amortization and depreciation	5,036	4,993
<b>EBITDA from continuing operations</b>	<b>6,600</b>	<b>18,617</b>
<i>Add (deduct) the impact of:</i>		
Share-based compensation	4,275	1,960
Loss on extinguishment of debt	1,662	—
Loss (gain) from revaluation of contingent consideration	327	1,827
Loss (gain) on disposal of fixed assets	8	(17)
Bad debt recovery	—	(4,169)
Unrealized and realized loss on investments	(14)	227
(Gain) loss on lease termination and derecognition of finance lease	(51)	(1,169)
Unrealized and realized foreign exchange (gain) loss	(214)	104
(Gain) loss on fair value of derivative liabilities and purchase option derivative assets	(669)	(2,922)
Other one-time items	1,793	1,176
<b>Adjusted EBITDA from continuing operations</b>	<b>\$ 13,717</b>	<b>\$ 15,634</b>
<i>Adjusted EBITDA Margin from continuing operations</i>	<i>18.5%</i>	<i>20.2%</i>

# Appendix – Reconciliation of Non-GAAP Measures

The table below reconciles Free Cash Flow for the quarters ended September 30, 2024 and June 30, 2024.

	For the Three Months Ended	
	September 30, 2024	June 30, 2024
Net cash provided by operating activities- continuing operations	\$ 1,823	\$ 13,129
Capital expenditures for property and equipment	(351)	(1,476)
Free Cash Flow	<u>\$ 1,472</u>	<u>\$ 11,653</u>

The table below reconciles General & Administrative expenses to General & Administrative expenses excluding stock-based compensation, bad debt and insurance recovery for the quarters ended September 30, 2024 and June 30, 2024.

	For the Three Months Ended	
	September 30, 2024	June 30, 2024
General & Administrative expenses	31,552	24,060
Less: stock-based compensation	4,275	1,960
Less: bad debt and insurance recovery	—	(5,040)
General & Administrative expenses excluding stock-based compensation, bad debt and insurance recovery	<u>\$ 27,277</u>	<u>\$ 27,140</u>